CASP3 and Duchenne muscular dystrophy: The results indicated a significant reduction in the resting cytosolic calcium level along with reduced caspase-3 (CASP3) activation and apoptosis in DMD iPSC-CMs, indicating the potential therapeutic benefit of this agent [35].